Get the Stockscreener App
878.50
0.59%
-5.46
Overview
News
Price History
Option Chain
Financials
Why LLY Down?
Discussions
Forecast
Stock Split
Dividend History
Lilly Eli Co stock is traded at $878.50, with a volume of 1.25M.
It is down -0.59% in the last 24 hours and up +0.06% over the past month.
Eli Lilly is a drug firm with a focus on neuroscience, cardiometabolic, cancer, and immunology. Lilly's key products include Verzenio for cancer; Mounjaro, Zepbound, Jardiance, Trulicity, Humalog, and Humulin for cardiometabolic; and Taltz and Olumiant for immunology.
See More
Previous Close:
$883.96
Open:
$878.13
24h Volume:
1.25M
Relative Volume:
0.40
Market Cap:
$785.01B
Revenue:
$65.18B
Net Income/Loss:
$20.64B
P/E Ratio:
38.89
EPS:
22.5894
Net Cash Flow:
$5.96B
1W Performance:
-4.47%
1M Performance:
+0.06%
6M Performance:
+6.34%
1Y Performance:
-0.65%
1-Day Range:
$872.20
$891.20
1-Week Range:
$871.73
$930.00
52-Week Range:
$623.78
$1,133.95
Lilly Eli Co Stock (LLY) Company Profile
Name
Lilly Eli Co
Sector
Industry
Phone
(317) 276-2000
Address
LILLY CORPORATE CTR, INDIANAPOLIS, IN
Compare LLY vs JNJ, ABBV, AZN, NVS
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
LLY
Lilly Eli Co
|
878.72 | 789.69B | 65.18B | 20.64B | 5.96B | 22.59 |
JNJ
Johnson Johnson
|
225.72 | 547.64B | 96.36B | 21.04B | 17.80B | 8.6488 |
ABBV
Abbvie Inc
|
197.83 | 351.47B | 61.16B | 4.19B | 17.82B | 2.3614 |
AZN
Astrazeneca Plc
|
187.99 | 294.27B | 58.80B | 10.24B | 8.98B | 3.2788 |
NVS
Novartis Ag Adr
|
144.72 | 277.58B | 54.72B | 14.02B | 15.32B | 7.1855 |
Lilly Eli Co Stock (LLY) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Mar-17-26 | Downgrade | HSBC Securities | Hold → Reduce |
| Feb-25-26 | Initiated | RBC Capital Mkts | Outperform |
| Feb-20-26 | Initiated | Barclays | Overweight |
| Jan-07-26 | Resumed | UBS | Buy |
| Dec-16-25 | Upgrade | Daiwa Securities | Neutral → Buy |
| Dec-15-25 | Reiterated | BofA Securities | Buy |
| Dec-15-25 | Reiterated | Goldman | Buy |
| Nov-13-25 | Initiated | Scotiabank | Sector Outperform |
| Nov-10-25 | Upgrade | Leerink Partners | Market Perform → Outperform |
| Oct-20-25 | Reiterated | BMO Capital Markets | Outperform |
| Oct-14-25 | Upgrade | Erste Group | Hold → Buy |
| Sep-17-25 | Downgrade | Berenberg | Buy → Hold |
| Aug-27-25 | Upgrade | HSBC Securities | Reduce → Hold |
| Aug-18-25 | Downgrade | Daiwa Securities | Outperform → Neutral |
| Aug-07-25 | Downgrade | Leerink Partners | Outperform → Market Perform |
| Jun-05-25 | Downgrade | Erste Group | Buy → Hold |
| Apr-28-25 | Downgrade | HSBC Securities | Buy → Reduce |
| Apr-22-25 | Initiated | Cantor Fitzgerald | Overweight |
| Dec-10-24 | Resumed | BofA Securities | Buy |
| Nov-15-24 | Initiated | Wolfe Research | Outperform |
| Oct-17-24 | Initiated | Bernstein | Outperform |
| Sep-13-24 | Resumed | Citigroup | Buy |
| Aug-12-24 | Upgrade | Deutsche Bank | Hold → Buy |
| Feb-21-24 | Downgrade | DZ Bank | Buy → Hold |
| Feb-16-24 | Reiterated | Morgan Stanley | Overweight |
| Dec-21-23 | Downgrade | Daiwa Securities | Buy → Outperform |
| Nov-09-23 | Initiated | Deutsche Bank | Hold |
| Oct-20-23 | Resumed | UBS | Buy |
| Aug-09-23 | Upgrade | Jefferies | Hold → Buy |
| Jul-26-23 | Reiterated | Citigroup | Buy |
| Jul-14-23 | Initiated | HSBC Securities | Buy |
| May-24-23 | Reiterated | BofA Securities | Buy |
| May-24-23 | Reiterated | UBS | Buy |
| Mar-13-23 | Upgrade | Wells Fargo | Equal Weight → Overweight |
| Mar-06-23 | Initiated | Jefferies | Hold |
| Feb-15-23 | Downgrade | Societe Generale | Hold → Sell |
| Nov-18-22 | Initiated | Credit Suisse | Outperform |
| Sep-22-22 | Upgrade | UBS | Neutral → Buy |
| May-23-22 | Initiated | SVB Leerink | Outperform |
| Apr-06-22 | Resumed | Morgan Stanley | Overweight |
| Mar-10-22 | Initiated | Daiwa Securities | Outperform |
| Jan-21-22 | Upgrade | DZ Bank | Hold → Buy |
| Jan-03-22 | Reiterated | Bernstein | Mkt Perform |
| Dec-17-21 | Initiated | Goldman | Neutral |
| Dec-16-21 | Reiterated | BMO Capital Markets | Outperform |
| Dec-16-21 | Reiterated | BofA Securities | Buy |
| Dec-09-21 | Resumed | Wells Fargo | Equal Weight |
| Nov-19-21 | Initiated | BMO Capital Markets | Outperform |
| Oct-11-21 | Upgrade | Berenberg | Hold → Buy |
| Sep-29-21 | Upgrade | Citigroup | Neutral → Buy |
| Aug-05-21 | Upgrade | DZ Bank | Hold → Buy |
| Jul-27-21 | Resumed | Truist | Buy |
| Jun-24-21 | Reiterated | Cantor Fitzgerald | Overweight |
| Jan-19-21 | Upgrade | Mizuho | Neutral → Buy |
| Dec-10-20 | Upgrade | Wolfe Research | Peer Perform → Outperform |
| Nov-10-20 | Resumed | Bernstein | Mkt Perform |
| Sep-29-20 | Initiated | Berenberg | Hold |
| Sep-03-20 | Upgrade | Morgan Stanley | Equal-Weight → Overweight |
| Jun-16-20 | Upgrade | Guggenheim | Neutral → Buy |
| Apr-21-20 | Downgrade | UBS | Buy → Neutral |
| Apr-09-20 | Downgrade | Morgan Stanley | Overweight → Equal-Weight |
| Feb-06-20 | Initiated | Mizuho | Neutral |
| Dec-18-19 | Upgrade | Morgan Stanley | Equal-Weight → Overweight |
| Oct-17-19 | Resumed | BofA/Merrill | Buy |
| May-28-19 | Initiated | Goldman | Buy |
| Apr-24-19 | Upgrade | Edward Jones | Hold → Buy |
| Apr-11-19 | Downgrade | Guggenheim | Buy → Neutral |
| Mar-12-19 | Initiated | JP Morgan | Overweight |
| Jan-23-19 | Initiated | UBS | Buy |
| Nov-26-18 | Downgrade | Citigroup | Buy → Neutral |
| Oct-31-18 | Upgrade | Credit Suisse | Underperform → Neutral |
| Oct-09-18 | Initiated | Guggenheim | Buy |
| Oct-01-18 | Reiterated | SunTrust | Buy |
| Sep-26-18 | Resumed | JP Morgan | Overweight |
View All
Lilly Eli Co Stock (LLY) Latest News
Sun Pharma, Eli Lilly Lead Latest Rush of Health-Care M&A - Bloomberg.com
Lilly to buy startup Ajax in bid for a better JAK drug - BioPharma Dive
Lilly to acquire Ajax Therapeutics for up to $2.3bn - BioXconomy
Lilly to buy local biotech for up to $2.3 Billion in cancer-drug push - The Boston Globe
Eli Lilly (LLY.US) to Acquire Blood Cancer Drug Developer for Up to USD2.3B - AASTOCKS.com
Eli Lilly (LLY) Stock: $2.3 Billion Ajax Therapeutics Deal Targets Blood Cancer - CoinCentral
Lilly snags Cambridge biotech for up to $2.3B in latest acquisition - The Business Journals
GLP-1 pill race heats up as Wegovy tablet holds strong against Lilly rival - Yahoo Finance UK
Global markets live: Eli Lilly, Meta Platforms, Microsoft, GSK… - marketscreener.com
Eli Lilly Enters $ 2.3 Billion Agreement to Acquire Ajax Therapeutics - Pharmaceutical Executive
Eli Lilly is acquiring blood cancer drug developer Ajax Therapeutics for up to $2.3 billion - qz.com
Lilly to Acquire Ajax Therapeutics Inc. - Contract Pharma
Lilly Buying Ajax Therapeutics For Up To $2.3 Billion To Advance Blood Cancer Pipeline - Pulse 2.0
Eli Lilly Q1 Preview: GLP-1 Momentum Meets the Novo Test - Moomoo
Lilly announces a new cancer deal, paying Ajax up to $2.3B for JAK inhibitor - Endpoints News
Lilly's M&A team strikes again with $2.3bn Ajax takeover - pharmaphorum
Should You Buy, Sell or Hold Lilly Stock Before Q1 Earnings? - Yahoo Finance
Eli Lilly to buy Ajax Therapeutics for up to $2.3 billion in blood cancer bet - Reuters
Eli Lilly buys Ajax Therapeutics for up to USD 2.3bn - medwatch.com
Lilly to Buy Ajax for Up to $2.3 Billion in Cancer-Drug Push - Bloomberg.com
Eli Lilly to buy Ajax Therapeutics for up to US$2.3 billion - BNN Bloomberg
Eli Lilly to Acquire Ajax Therapeutics for Up to $2.3 Billion Cash - marketscreener.com
Leerink raises Eli Lilly stock price target to $1,296 on pipeline - Investing.com
Eli Lilly to buy Ajax Therapeutics for up to $2.3 billion - marketscreener.com
Leerink Partners Adjusts PT on Eli Lilly and Co. to $1,058 From $1,296, Maintains Outperform Rating - marketscreener.com
Lilly to Acquire Ajax Therapeutics in Up to $2.3 Billion Oncology Deal - citybiz
Eli Lilly to buy Ajax Therapeutics for up to $2.3B - Breakingthenews.net
Lilly to acquire Ajax Therapeutics for up to $2.3 billion By Investing.com - Investing.com Canada
Lilly to acquire Ajax Therapeutics for up to $2.3 billion - Investing.com
Lilly to acquire Ajax Therapeutics to advance outcomes for patients with myelofibrosis and polycythemia vera - PR Newswire
EXCLUSIVE: UAE clinic says thousands join waitlist for Eli Lilly’s weight-loss pill after early approval - Arabian Business
Mag 7 Earnings Bonanza, Fed Await Stocks at Record Highs: What to Expect - Investing.com
Eli Lilly and Company’s (LLY) Foundayo Gets Prescribed 3,707 Times in the US in Second Week of Launch, Reuters Reports - Insider Monkey
Eli Lilly and Company (LLY): Among the Best Stocks to Buy While the Market Is Down - Insider Monkey
Eli Lilly and Company (LLY): One of the Top Low Risk High Growth Stocks? - Yahoo Finance
Is Eli Lilly Stock Worth Watching Right Now - Kalkine Media
KLP Kapitalforvaltning AS Has $331.30 Million Position in Eli Lilly and Company $LLY - MarketBeat
Branded Pharma Q4 Earnings Review: Merck and Eli Lilly Performance Analysis 2026News and Statistics - IndexBox
Eli Lilly and Company $LLY Shares Purchased by Caprock Group LLC - MarketBeat
Fishman Jay A Ltd. MI Buys 1,344 Shares of Eli Lilly and Company $LLY - MarketBeat
Eli Lilly Weight Loss Pill Records Modest Second Week Sales - HarianBasis.co
Should You Add a Healthcare Stock to Your Portfolio This Month? And Should It Be Eli Lilly (LLY)? - The Motley Fool
Why Eli Lilly (LLY) Shares Are Trading Lower Today - Yahoo Finance
Ticino Wealth Makes New $1.31 Million Investment in Eli Lilly and Company $LLY - MarketBeat
Optas LLC Has $4.18 Million Position in Eli Lilly and Company $LLY - MarketBeat
PFG Advisors Sells 3,261 Shares of Eli Lilly and Company $LLY - MarketBeat
LLY Stock Quote Price and Forecast - CNN
$Eli Lilly and Co (LLY.US)$ Monday 917 and will keep up for few more days. - Moomoo
Why Eli Lilly Stock Flopped on Friday - Yahoo Finance
Eli Lilly and Co (LLY) Stock Down 3.7% -- Now Undervalued? GF Sc - GuruFocus
Eli Lilly and Company (NYSE:LLY) Trading Down 3.6%Time to Sell? - MarketBeat
Lilly Eli Co Stock (LLY) Financials Data
Revenue
Net Income
Cash Flow
EPS
0.84%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):